FMP
PNK
Inactive Equity
MabCure Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers. The company was formerly known as Smartec Holdings, Inc. and changed its name to MabCure Inc. in January 2008 to reflect its new business plan. MabCure Inc. was founded in 2006 and is based in White Plains, New York.
0.000016 USD
-0.0001 (-625%)
Valuation Date:
Apr 18, 2024 12:20 PM
Share Price on Valuation Date
$0
Stock Beta
13.664
Shares Outstanding
32182000000